权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Novel Tools for the Noninvasive Evaluation of the Human Placenta

用于人类胎盘无创评估的新工具

基本信息

批准号：
9019463
负责人：
Alfred Z Abuhamad
金额：
$ 72.6万
依托单位：
EASTERN VIRGINIA MEDICAL SCHOOL
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-09-17 至 2019-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9019463
关键词：
Algorithms Americas Biometry Biopsy Blood Vessels Breast Microcalcification Cardiovascular system Child Clinical Research Collaborations Color Control Groups Data Development Discipline of obstetrics Early identification Ensure Evaluation Fetal Growth Retardation Fetus Fibrinogen Functional disorder Future Gene Expression Profile Goals Human Image Imagery Industry Leadership Letters Measurement Medical Methods Microscopic Morphologic artifacts Mothers Motion Neonatal Nomograms Organ Outcome Outcome Study Pathologic Pathology Performance Perfusion Placenta Placentation Play Pre-Eclampsia Pregnancy Pregnancy Outcome Pregnant Women Premature Birth Prenatal care Prevention Research Design Resolution Risk Risk Factors Role Structure System Technical Expertise Techniques Technology Testing Time Tissues Translational Research Ultrasonography Vascular remodeling Woman adverse outcome at-risk pregnancies base body system cohort design elastography fetal high risk image processing imaging modality improved in vivo indexing longitudinal design novel prevent primary outcome public health relevance research and development soft tissue technology development tool

项目摘要

DESCRIPTION (provided by applicant): Mounting evidence suggests that abnormal placental development in early gestation is highly associated with many maternal and fetal pathologic conditions, which can manifest later in pregnancy. The ability to evaluate in real time human placental structure and function in early gestation by using novel ultrasound tools will allow for the identification of early markers of placental dysfunction with the ultimate long- term goal of prevention of adverse pregnancy outcomes. As initial steps in accomplishing this long-term goal, we propose this study designed to find which of the novel ultrasound tools are best at discriminating between women who will develop adverse pregnancy outcomes and those who will not. We have formed collaboration with Toshiba Medical Systems, one of the ultrasound industry leaders, that is focused on evaluating recently developed novel ultrasound tools that substantially expand our ability to study placental structure and function in vivo. This collaboration will advance the field through technology development and translational research. Our collaboration brings together novel tools, strong technological expertise, leadership in obstetrical ultrasound, and a track record of clinical research. The novel ultrasound tools that will be used in our study include Superb Micro-Vascular Imaging (SMI) for the comprehensive assessment of placental microvasculature, Shear Wave Elastography (SWE) for the evaluation of placental tissue stiffness and MicroPure(r) for the visualization of placental microcalcificatios content. We plan to apply these novel ultrasound tools, along with fetal and placental biometric and 3D ultrasound measurements, on a control group of normal pregnancies and a study group of at-risk pregnancies starting from early gestation and in a longitudinal cohort design. Maternal and neonatal outcome will be collected along with storage of biospecimen and placental pathology for future evaluation. Pregnancy ending at less than 37 0/7 weeks' gestation for any cause will be the primary study outcome and will differentiate normal from abnormal pregnancy. The ultrasound data will be analyzed to identify significant early markers of placental dysfunction. We have 3 study aims. First is to develop longitudinal nomograms for the novel ultrasound tools in normal human pregnancies. Second is to apply these novel ultrasound tools to study placental development in at-risk human pregnancies. Third to develop and evaluate an overall novel placental ultrasound marker: "The Placental Index" as an early gestation, non-invasive, marker of placental dysfunction for the prediction of adverse human pregnancy outcomes.